Concerns regarding the use of dabigatran for stroke prevention in atrial fibrillation

Area of Science:

• Pharmacology
• Cardiology
• Internal Medicine

Background:

• Dabigatran is an oral direct thrombin inhibitor approved for stroke prevention in atrial fibrillation.
• It serves as an alternative to traditional vitamin-K antagonists.
• Despite its approval, several clinical aspects remain unclear.

Purpose of the Study:

• To provide an overview of the concerns and unresolved issues associated with dabigatran.
• To highlight areas needing further research and clinical guidance.

Main Methods:

• Literature review of existing studies and clinical guidelines.
• Synthesis of current knowledge on dabigatran's use and limitations.

Main Results:

• Key concerns include the need for standardized laboratory monitoring.
• Uncertainties exist regarding optimal use in elderly patients and those with renal insufficiency.
• Drug- and food-interactions require careful consideration.
• The absence of a specific antidote poses a significant clinical challenge.

Conclusions:

• Further research is essential to address the identified concerns regarding dabigatran.
• Clinical guidelines need to be developed for laboratory monitoring, special populations, and managing bleeding events.
• Addressing these issues will optimize the safe and effective use of dabigatran.